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While pralatrexate (PDX) has been successfully developed for the treatment of T-cell
lymphoma, the mechanistic basis for its T-cell selectivity and acquired resistance
remains elusive. In an effort to potentially identify synergistic combinations that
might circumnavigate or delay acquired PDX resistance, we generated resistant cells
lines over a broad concentration range. PDX-resistant cell lines H9-12 and H9-200
were developed, each exhibiting an IC50 of 35 and over 1000 nM, respectively.
These lines were established in vitro from parental H9 cells. Expression analysis of
the proteins known to be important determinants of antifolate pharmacology rev-
ealed increase expression of dihydrofolate reductase (DHFR) due to gene amplifica-
tion, and reduced folate carrier1 downregulation, as the putative mechanisms of
resistance in H9-12 and H9-200 cells. Cross resistance was only seen with metho-
trexate but not with romidepsin, azacitidine (AZA), decitabine, gemcitabine, doxorubi-
cin, or bortezomib. Resistance to PDX was reversed by pretreatment with
hypomethylating agents in a concentration-dependent fashion. Comparison of gene
expression profiles of parental and resistant cell lines confirmed markedly different
patterns of gene expression, and identified the dual specificity phosphatase four
(DUSP4) as one of the molecular target of PDX activity. Reduced STAT5 phosphory-
lation following exposure to PDX was observed in the H9 but not in the H9-12 and
H9-200 cells. These data suggest that combination with hypomethylating agents
could be potent, and that DUSP4 and STAT5 could represent putative biomarkers of
PDX activity.
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1 | INTRODUCTION
Folate metabolism plays a central role in multiple biological path-
ways and an unbalanced folate metabolism has been implicated in
the pathogenesis of different diseases, including lymphomagenesis.1
Pralatrexate (PDX) was the first drug approved for patients with
relapsed/refractory peripheral T-cell lymphoma (PTCL). Unlike other
folates, PDX was designed to have high affinity for the reduced
folate carrier (RFC), which internalizes both natural forms of folic
acid and antifols. This rapid and efficient internalization leads to rel-
atively high intracellular concentrations. While PDX inhibits many of
the same enzymes inhibited by other antifols like methotrexate
(MTX), it is clear that its activity in PTCL goes well beyond the inhi-
bition of these pathways. This is underscored by the fact that
leucovorin does not mitigate its activity, which is the case for classi-
cal antifolates like MTX, and suggests that there are other targets
the drug influences in PTCL that account for some component of its
efficacy.2
Although PDX is significantly more cytotoxic when compared to
first-generation antifolates, its precise mechanism of action and T-cell
malignancy is not completely understood. PDX received regulatory
approval for the treatment of relapsed or refractory PTCL in 2009.
Early preclinical and clinical experiences have suggested an extraordi-
narily high level of activity in T-cell malignancies, with minimal to no
activity in patients with B-cell lymphoid neoplasm or carcinomas.3-5
Despite the greater selectivity of PDX against T-cell lymphomas, the
overall response rate (ORR) in heavily treated patients is about 30%,
though recent data from studies in Asia suggest ORR in the 50%.6,7
Several lines of data suggest that PDX use earlier in the line of ther-
apy can improve the ORR to about 45% to 50%, and lead to markedly
better complete remission rates, and progression free and overall sur-
vival. This latter observation suggests that there is cross-resistance
with other conventional cytotoxic chemotherapy agents which accu-
mulates over time.8
Intrinsic resistance to PDX appears to be overcome to some
extent through the use of combinations, as preclinical and clinical data
evaluating PDX combinations have shown marked synergy with his-
tone deacetylase inhibitors (HDACi) like romidepsin,9 proteasome
inhibitors like bortezomib,10 and cytidine analogs.11 For example,
while the ORR to single agent PDX and romidespin are about 30%
and 25%, respectively, the ORR to PDX plus romidepsin in a phase
1 study is in the 70% to 75% range, with a complete response rate of
29%..9,12,13
While the mechanistic basis for the PTCL selectivity and acquired
resistance to PDX are still not entirely understood, it is clear the T-cell
malignancies represent one of those neoplastic diseases characterized
by high rates of intrinsic drug resistance, and a penchant for rapid
emergence of acquired resistance. Herein, we have developed a series
of PDX-resistant cell lines as a strategy to better understand mecha-
nisms of acquired resistance and as a strategy to potential identify
companion agents that might overcome mechanisms of intrinsic
resistance.
2 | MATERIALS AND METHODS
2.1 | Materials
All drugs were purchased from Selleckchem (Houston, Texas) and
were prepared in 100% DMSO.
2.2 | Cell lines and culture
The cutaneous T-cell lymphoma line H9 was obtained from the Ameri-
can Type Culture Collection (Manassas, Virginia). Parental and derived
resistant cells were grown in RPMI 1640 medium with 10% fetal
bovine serum.
2.3 | Western blotting
Western blotting was performed according to standard protocols,
using chemiluminescence detection system (Thermo Scientific, Wal-
tham, Massachusetts). Primary antibodies against SLC19A1
(ThermoFisher, Waltham, Massachusetts), DHFR (Santa Cruz, Dallas,
Texas), dual specificity phosphatase four (DUSP4), STAT5, phospho-
STAT5 and β actin (Cell Signaling, Danvers, Massachusetts).
2.4 | Cytotoxicity assays
Cytotoxicity was performed on cultured cells using the Cell Titer Glo
assay (Promega, Madison, Wisconsin) as previously described.10 Syn-
ergy of the combinations was calculated using Excess Over Bliss
methodology.10 Luminescence was detected using the multimode
plate reader GloMax Discover system (Promega, Madison, Wisconsin).
For the pretreatment with AZA and decitabine, cell were exposed for
4 days to increased concentration of the hypomethylating agent
(125, 250, and 500 nM for AZA and 6.25, 12.5, and 25 nM for deci-
tabine). The compound was added to the cell culture every 24 hours
for a 96-hour period. Then, cells were washed and seeded at concen-
tration of 3 × 105 cells/mL and exposed to increased concentration
of PDX.
2.5 | Generation of PDX resistant cells
H9 cells were seeded at concentration of 3 × 105 cells/mL into
75 cm2 culture flasks. To establish PDX resistance, the cells were ini-
tially incubated with low concentrations of PDX for 96 hours, then
counted and reseeded. Concentrations of PDX were gradually
increased and the process continued until the concentration of PDX
in the medium reached between 30 and 200 nM after 160 days. Two
H9-derived cell lines were obtained that grew stably in medium con-
taining PDX at concentration of 10 and 200 nM.
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2.6 | Quantitative reverse transcription
polymerase chain reaction
RNA samples extracted from wild-type and resistant cell lines were used
for gene expression profiling and reverse transcription polymerase chain
reaction (RT-qPCR) analysis. cDNA was made using Omisncript RT Kit
(Qiagen, Hilden, Germany). Taqman Fast Advanced Master Mix and FAM-
MGB primers were purchased from Thermo Fisher (Waltham, Massachu-
setts). RFC (Hs00953344_m1), folylpolyglutamate synthetase (FPGS)
(Hs00191956_m1), DHFR (Hs00758822_m1), gamma-glutamyl hydrolase
(GGH) (Hs00914163_m1). Reactions were conducted on a StepOnePlus
Real-Time PCRSystem (Applied Biosystem, Foster City, California).
2.6.1 | Methylation specific PCR
Genomic DNA was extracted using a Quick-DNA kit (Zymo Research,
Irvine, California) and bisulfite treatment was carried out using a EZ
DNA Methylation kit (Zymo Research, Irvine, California) following the
manufacturer's instructions. Primers specific for the RFC promoter A
and B regions and reaction condition were as previously described.14
2.7 | Gene expression profiling
Total RNA was extracted using RNeasy mini kit (Qiagen, Hilden, Ger-
many) from cells collected after 24 hours incubation with or without
drugs (MTX and PDX) and RNA quantitation and quality over assessed
by the Agilent Bioanalyzer 2100. RNA libraries prepared from poly-A
pull-down enrich mRNAs (Illumina TruSeq RNA prep kit, San Diego, Cal-
ifornia), were sequenced at the Columbia Genome Center using Illumina
HiSeq2500/HiSeq4000. DEseq software, an R package based on a neg-
ative binomial distribution that models the number reads from RNA-seq
experiments and test for differential expression, was employed to test
for differentially expressed genes under various conditions. For visuali-
zation, raw counts were normalized sample-wise to reads per million
and differential expression was calculated for each cell line as a z-score
centered at untreated controls. Hierarchical clustering was calculated
by euclidean distance using the hclust function in the stats R package
and visualized using the heatmap.2 function within the gplots R pack-
age. Unclustered heat maps were also generated with the heatmap.2
function with samples organized by cell line and drug concentrations
and genes organized by pathway annotation. Principal component anal-
ysis (PCA) was prcomp function in the stats R package. In the matrix,
each column represents a sample and each row represents a gene.
3 | RESULT
3.1 | Differential H9, H9-12, and H9-200 cells
sensitivity to folate antagonist
Two drug resistant cell lines, named H9-12, and H9-200, were derived
from exponentially growing H9 cells, following exposure to increased
PDX concentrations. H9-12 and H9-200 cells showed no sensitivity
to drug concentrations that clearly induce cell death in the H9 paren-
tal cell line, indicating the emergence of a resistant phenotype. Cell
viability of H9-12 cells was not affected by a 20-fold increase in drug
concentration relative to H9 parental cells while H9-200 cells showed
no sensitivity to all tested PDX concentrations (≥1 mM). Figure 1
shows the sensitivity of H9, H9-12, and H9-200 cell lines to increas-
ing concentrations of both PDX and MTX. All cell lines exhibited a
concentration-dependent resistance to PDX and MTX, though PDX
retains about 1-log greater potency than MTX across the three cells
lines.
A significant fold increase was observed in the concentration of
PDX and MTX required to affect cell viability by 50% in drug resistant
cells relative to their corresponding parental cells. The IC50 for
PDX and MTX, after 48 hours of drug exposure, were estimated to
be 3.3 and 6.4 nM for H9 cells, 34 and 170.2 nM for H9-12 cells,
and >1000 and 4073 nM for H9-200 cells, respectively (Figure 1
and Supporting information Figure 1).
In order to evaluate the stability of the drug resistance pheno-
type, the H9-12 and H9-200 cell lines, grown for over a month in
absence of drug, were reexamined for their relative sensitivity to
increase concentration of PDX. H9-12 and H9-200 cells, grown in
absence of drug, still demonstrated resistance to PDX when compared
to the H9 parental cell line. The IC50 for PDX was 14.17 nM for
H9-12 and >1000 nM for H9-200 (Supporting information Figure 1).
3.2 | H9, H9-12, and H9-200 display similar
sensitivity to HDACi, AZA, decitabine, doxorubicin,
gemcitabine, and bortezomib
To evaluate the patterns of resistance to other drugs, H9, H9-12, and
H9-200 were exposed to increased concentrations of the HDACi
romidepsin, two hypomethylating agents (AZA and decitabine), an
anthracycline (doxorubicin), the synthetic pyrimidine nucleoside
prodrug gemcitabine and the proteasome inhibitor bortezomib. Con-
centration and time dependent sensitivity of the parental and the two
resistant cell lines to all six single agents were similar (Figure 2 and
Supporting information Figure 2). The estimated IC50s at 48 hours
from exposure were 3.1 nM for romidepsin, 0.9 μM for AZA,
>100 μM for decitabine, 168.7 nM for doxorubicin, 5.9 nM for
gemcitabine, and 4.3 nM for bortezomib.
3.3 | Differential expression of DHFR, FPGS, GGH,
and RFC in the H9, H9-12, and H9-200 cells
Mechanisms of resistance to folate antagonists has been correlated to
deregulated expression of DHFR, GGH, FPGS, and RFC.12,15-20 In
order to identify those traditional molecular mechanisms that would
explain the patterns of antifol resistance we quantitated the expres-
sion of the DHFR, FPGS, GGH, and RFC genes in the H9 parental cell
line and the two PDX resistant cell lines H9-12 and H9-200 as deter-
mined through RT-qPCR, western blot analysis and
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immunocytochemistry (IHC). As shown in Figure 3A, when compared
to the parental H9 cells, a substantial increase (5-fold) in RNA levels
for the DHFR gene was identified in the H9-12 cell line. Increase
(0.5-fold) in DHFR RNA levels was also observed in the H9-200 cells
though of a lesser extent. Western blot analysis confirmed a
corresponding increase in DHFR protein levels in the H9-12 and
H9-200 cells (Figure 3B). Increased GGH and reduced FPGS protein
levels were also identified in H9-12 and H9-200 cells when compared
to parental H9 cells, but without a clear relationship with the
observed RNA levels. Finally, a substantial decrease in RNA levels for
the RFC gene was observed in the H9-200 cells compared to H9 and
H9-12 cells (Figure 3A). IHC analysis of the RFC protein expression in
parental and drug resistant cell lines, correlated with the differential
expression observed at the RNA level (Figure 3C).
These data suggest that the molecular mechanism mainly respon-
sible for PDX/MTX resistance in the H9-12 cells is the over expres-
sion of the DHFR gene, while in the H9-200 cells, the principle
mechanism of resistance was reduced RFC expression. Thus, two dis-
tinct concentration dependent patterns of PDX resistance. Based on
these findings, we sought to determine the genetic basis for the
resistance.
3.4 | DHFR gene amplification and MSP-PCR
analysis of RFC promoter
As has been shown by the seminal work of Bertino and
coworkers,19,21,22 resistance to MTX has been attributed to increased
expression of DHFR through DHFR gene amplification. As shown in
Figure 4A, cytogenetic analysis of H9, H9-12, and H9-200 using fluo-
rescence in situ hybridization analysis with a two color DHFR fluores-
cent probe established the presence of 2, 10 and 4 copies of the
DHFR gene, respectively. These data confirm that the increased
expression of the DHFR gene in the H9-12 and H9-200 cell lines was
the result of gene amplification.
Epigenetic dysregulation can also play an important role in drug
resistance, by silencing genes controlling the major determinants of
antifol sensistivity and resistance. Methylation of the RFC promoter
has been reported as the underlying mechanism for the antifolate
resistance observed in colorectal cancer,23 systemic lupus
erythematosus,24 the MTX resistant cell line M805, established from
a patient with malignant fibrohistocytoma14 and the breast cancer cell
line MDA-MB-231, where a 1400 bp RFC promoter region was identi-
fied as a CpG island and found methylated.14,25 We explored the
F IGURE 1 H9, H9-12, and H9-200 differential sensitivity to pralatrexate (PDX) and methotrexate (MTX). Growth inhibition curves following
24, 48, and 72 hours exposure of H9 (blue), H9-12 (red), and H9-200 (green) cells to increased PDX or MTX concentrations. IC50 values given in
nanomolar concentrations for each time point. Error bars represent the SD of three or more separated experiments [Color figure can be viewed at
wileyonlinelibrary.com]
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methylation status of the RFC promoter in the H9, H9-12, and
H9-200 cell lines via methylation specific PCR, using as positive con-
trol the genomic DNA extracted from the MDA-MB-231 cell line. As
shown in Figure 4B, neither promoter region A nor B shows any evi-
dence of methylation at genomic level in H9, H9-12, and H9-200 cells
when compared to MDA-231 cells. This result excludes the likelihood that
reduced expression of the RFC gene in the H9-200 cells is due to promoter
methylation. Rothem et al26 have reported that reduced expression of tran-
scription factors as CREB1, ATF1, USF1, FOS, JUN, Sp3, and Sp1 is
responsible for a major decrease in RFC mRNA expression in the CCRF-
CEM and derived human leukemia cell lines. Hence, we then explored any
potential relationship between the expression of these transcription factors
and the reduced RFC seen in H9-200. Western blot analysis of H9, H9-12,
and H9-200 cells showed a similar level of expression for the transcription
factor USF1 in all three cell lines, but a reduced level of expression of the
transcription factors Sp1, Sp3 and JUN in H9-12 and H9-200 when com-
pared to parental H9 cells (Supporting information Figure 3). H9-12 cells
do not show decreased RFC expression, thus taking in consideration the
differential expression of RFC in H9-12 and H9-200 we can exclude that
the decrease expression of the RFC gene in H9-200 is the result of a
reduced availability of the Sp3 and JUN transcription factors.
Although promoter methylation was not the reason for the lower
RFC expression, we explored the potential of global genome wide
methylation on the lower levels of RFC in H9-200. We treated cells
with 5-azacytidine (AZA) and decitabine (DAC) in order to determine
if these hypomethylating agents could restore RFC expression and
consequently sensitivity to PDX. As first step, H9, H9-12, and H9-200
were exposed to increased concentrations of AZA and DAC. Concen-
tration and time dependent sensitivity of the parental and the two
resistant cell lines to the two single agents were similar (Figure 1),
again confirming minimal to no cross-resistance to these drugs. The
estimated IC50s at 48 hours from exposure were 0.9 μM for AZA and
>100 μM for DAC. As we and others have demonstrated in the past,
maximal demethylation requires continuous exposure to the hypo-
metylating agent.27 Continuous exposure to AZA with 24 hours inter-
val replacement demonstrated that H9, H9-12, and H9-200 cells
demonstrated a 2- to 4-fold increase in RFC mRNA level as deter-
mined by qPCR analysis (Figure 4C). A 2-fold increase in RFC mRNA
level was observed in H9 and H9-12 cells while a 4-fold increase was
seen in the H9-200 cells (Figure 4C). However, the RFC mRNA level in
the H9-200 exposed to AZA was substantially reduced when com-
pared to H9 and H9-12 mRNA levels.
F IGURE 2 H9, H9-12, and H9-200 similar sensitivity to romidepsin, azacitidine, and decitabine. Growth inhibition curves following 24 (blue),
48 (red), and 72 (green) hours exposure to increased drug (Romidepsin, Azacitidine, and Decitabine) concentrations. IC50 values given in
nanomolar and micromolar concentration for each time point. Error bars represent the SD of three or more separated experiments [Color figure
can be viewed at wileyonlinelibrary.com]
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3.5 | Pretreatment with hypomethylating agents
restore PDX sensitivity in H9-200 cells
As noted above, all three cell lines were equally sensitive to the hyp-
omethylating agents, and exposure to AZA induced an increase in the
RFC mRNA level in parental, H9-12, and H9-200 cell lines. To
explore this further, H9, H9-12,and H9-200 were continuously
exposed to increasing concentration of AZA and decitabine for
96 hours and then reanalyzed for their sensitivity to PDX. As
shown in Figure 5A,B, an increase in concentration and time
dependent PDX sensitivity of H9 and H9-200 cells was observed
after AZA and decitabine pretreatment, with a minimal effect
F IGURE 3 Gene expression of folate pathway genes in H9, H9-12, and H9-200 cell lines. A, Dihydrofolate reductase (DHFR),
folylpolyglutamate synthetase (FPGS), gamma-glutamyl hydrolase (GGH), and reduced folate carrier (RFC) mRNA levels in H9-12 and H9-200 cells
determined by quantitative real-time RT-PCR as compared to H9 parental cells. Arrows indicate DHFR and RFC RNA levels. B, DHFR, FPGS and
GGH protein levels in H9, H9-12, and H9-200 cells as determined by Western blot analysis. C, Immunohystochemistry analysis of RFC expression
in H9, H9-12, and H9-200 [Color figure can be viewed at wileyonlinelibrary.com]
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observed in H9-12 cells, expressing high levels of DHFR. Increased
sensitivity to PDX in H9-200 correlates with increased exposure
to 5-AZA and DAC, indicating that the resulting resensitization to
PDX was due, at least in part, to the hypomethylating agent
pretreatment.
3.6 | Gene expression profiling of H9, H9-12, and
H9-200 reveals two patterns of modulation
To gain deeper insight into the mechanisms of action and the molecu-
lar pathways affected by MTX and PDX, gene expression profiles
(GEP) of parental and resistant T-cell lymphoma lines (H9, H9-12, and
H9-200) exposed to single agents drugs were performed.
Unsupervised hierarchical clustering and PCA revealed a clear distinc-
tion and close distribution based on cell types and treatment, indicat-
ing the consistency of the experiments as well as the specificity of
treatment effects (Supporting information Figure 4).
GEP on parental H9 cells treated with MTX or PDX revealed that
1890 genes were modulated by MTX vs 2083 genes modulated by
PDX. The relationship among the GEP are shown in Figure 6A. The
number of genes modulated in common by PDX and MTX was 1215
genes; 675 of the 1890 MTX-modulated genes were unique to MTX
only, while 860 of the 2083 genes modulated by PDX were unique to
PDX. Validation of gene expression analysis was performed by RT-
qPCR using five selected genes (AK1, DUSP4, GIMAP6, SAT1, STC1),
and successfully confirmed the genes found to be up-regulated in the
differential expression analysis (Figure 6B).
Gene set enrichment analysis on the common and unique gene
sets identified four canonical pathways (immune system, cell cycle,
MYC activation pathway and hemostasis), affected by exposure to
both MTX and PDX. An additional 43 and 33 genes that belong to the
immune system and cell cycle were affected by exposure to MTX but
not PDX. In contrast, exposure to PDX but not MTX affected 47 genes
that belong to the metabolism of proteins canonical pathway. Lastly,
exposure to both single agents affected the metabolism of RNA
F IGURE 4 Dihydrofolate reductase (DHFR) gene amplification and MS-PCR analysis of reduced folate carrier (RFC) promoter region. A, DHFR
cytogenetic analysis of H9, H9-12, and H9-200 cells using two colors fluorescence in situ hybridization analysis. Arrows indicate signals relative
to amplified DHFR gene in metaphase chromosome spreads. B, RFC promoter methylation specific PCR in H9, H9-12, H9-200, and MDA-231
cells. C, RFC mRNA level quantitative analysis in H9, H9-12, and H9-200 cells exposed to increased concentration of azacytidine (AZA) for
96 hours. Samples were normalized to RFC mRNA level in DMSO treated H9 cells. Bars represent SD of three determinations. For all the analyses
similar results were obtained in three independent determinations. Top right histogram shows an enhanced representation of the induced RFC
mRNA expression by azacitidine in the H9-200 cells. DMSO, dimethyl sulfoxide; MS-PCR, methylation specific polymerase chain reaction [Color
figure can be viewed at wileyonlinelibrary.com]
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pathway but by modulating different (nonoverlapping) set of genes,
20 in case of MTX, 40 for PDX (Figure 6C). A supervised analysis of
the genes whose expression is modulated (adjusted P value .05, abso-
lute Log 2-fold change 0.5, Supporting information Tables 1 and 2) by
each single agent is shown in Figure 6D. Three patterns of modulation
were identified: (a) genes whose expression is modified by both
agents, (b) genes whose expression is more substantially modified by
MTX than PDX, and (c) genes whose expression is more substantially
modified by PDX than MTX. Interestingly, none of the patterns are
seen in the two resistant cell lines H9-12 and H9-200 following expo-
sure to MTX or PDX.
The DUSP4 was among the genes whose expression was found
upregulated after exposure to MTX or PDX (Figure 6B,C). As shown in
Figure 6E, increase in DUSP4 protein level was also observed, when
H9 and MyLa, two CTCL derived cell lines and TLOM1, an adult T-cell
leukemia derived cell line, were exposed to PDX. DUSP4 has been
showed to regulate STAT5 stability in T cells28 and suppress CD4 T
cell proliferation through regulation of STAT5 phosphorylation and
IL-2 signaling.29 As shown in Figure 6E a decrease in STAT5 phos-
phorylation was observed in parental H9 but not in H9-12 and
H9-200 resistant cells. Interestingly, the decrease in STAT5 phosphor-
ylation correlates with a corresponding increase in DUSP4 expression.
4 | DISCUSSION
The development of drug resistant cell lines can represent a valuable
tool in understanding mechanisms of intrinsic and acquired drug resis-
tance, and can provide insights in mechanism of action.30,31 Resis-
tance to antifolates has been ascribed to several mechanisms,
F IGURE 5 Azacitidine (AZA) and decitabine (DAC) synergize with pralatrexate (PDX) in H9, H-12, and H9-200 cells. A, AZA and B, DAC
pretreatment sensitizes H9-12 and H9-200 cells to PDX. Sequential exposure to increase concentration of hypometylating agent decreases
resistance to PDX. Error bars represent the SD of three or more separated experiments. Excess Over Bliss (EOB) values represent average of
three independent experiments. AZA, DAC, PDX. Concentration values are in nM [Color figure can be viewed at wileyonlinelibrary.com]
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including increased levels of the target through gene amplification, or
genes involved in drug elimination, silencing of internalizing trans-
porters, encompassing transport of the drug, and down-regulation
of genes involved in enhancing its intracellular cytotoxic-
ity.14,20,25,26,32,33 We demonstrated herein that in two PDX resis-
tant cell lines, H9-12 and H9-200, DHFR gene amplification and
reduced RFC1 mRNA expression represent the two major mecha-
nisms resulting in resistance to MTX and PDX, respectively
(Figure 7). Pretreatment with hypomethylating agents as AZA and
decitabine appear to mitigate some of the observed resistance,
although the pretreatment has a more robust effect on H9-200
cells than the H9-12 cells. This suggests that the hypomethylating
agent is able to overcome the mechanisms of resistance related to
RFC down-regulation, and not the DHFR amplification. It is possible
in fact that the elevated DHFR expression in the H9-12 cell line
could be worsened by exposure to the hypomethylating agent,
resulting in a further increase in RNA transcriptional levels and
increased expression of the DHFR gene.
Although the GEP of parental and resistant cell lines after PDX
and MTX exposure revealed perturbation of common pathways, the
number and type of differentially expressed genes within the common
pathways diverge, suggesting that there are substantial differences
between these drugs. The notion that PDX has a different mechanism
of action making it noncross resistant to MTX has been supported by
clinical data, and the observation that leucovorin does not nullify all
of its cytotoxic effects.5 In this instance, the comparison of GEP
analysis of parental and resistant cell lines, exposed to MTX and
PDX, could provide mechanistic insights into the differential effects
F IGURE 5 (Continued)
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F IGURE 6 Methotrexate (MTX) and pralatrexate (PDX) modulate unique set of genes. A, The Venn diagram shows the relationship among
genes included in the two signatures (adjusted P value ≤.05). The expression of 675 and 868 genes, uniquely modulated by each agent treatment.
Number of genes modulated by both agents are also shown. B, Validation of the gene expression profiles (GEP) analysis performed by reverse
transcription polymerase chain reaction (RT-qPCR) using five selected genes (AK1, dual specificity phosphatase four [DUSP4], GIMAP6, SAT1 and
STC1). C, Canonical pathways commonly and uniquely affected by MTX and PDX. D, Supervised analysis of TCL lines based of the expression of
genes modulated by each single agent (adjusted P value .05, Log 2-fold change value ≥0.5). Commonly and uniquely gene sets modulated by MTX
and PDX are indicated. E, Western blot analysis of H9, H9-12, H9-200 (DUSP4, phospho-STAT5 and STAT5), MyLa and TLOM1 (DUSP4) cells
exposed 24 hours to MTX and PDX [Color figure can be viewed at wileyonlinelibrary.com]
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of these drugs, as well as possible mechanism of action, in T-cell
lymphoma.
The identification of DUSP4 as one of the genes whose expres-
sion is increased in H9, MyLa and TLOM1 cells following exposure to
PDX is also an example of how we could use this information to gen-
erate hypotheses around mechanism. DUSP4 is a member of the dual
specificity protein phosphatatse subfamily and DUSPs have been
implicated in T-cell lymphomagenesis. These phosphatases negatively
regulate members of the mitogen-activated kinase superfamily
involved in cellular proliferation and differentiation.
Reduced expression of DUSP4 has been identified as an
adverse feature in different tumor types and cancer derived cell
lines34-37 and found to be epigenetically silenced in 75% of cases
of diffuse B cell lymphoma (DLBCL). Moreover, a lack of DUSP4
was a negative prognostic factor in three independent cohorts of
DLBCL patients.38 An increase in DUSP4 mediated by PDX would
theoretically counterbalance the adverse pathogenetic implica-
tions of reduced DUSP4.
These findings are further supported by our observation of STAT5
decreased phosphorylation in H9 but not in H9-12 and H9-200 exposed
to PDX. DUSP4 has shown to regulates STAT5 phosphorylation,28 and
recent findings show that STAT5 activation drives PTCL,39 while its inhi-
bition induces apoptosis in PTCL.40 Pimozide, an FDA-approved neuro-
leptic agent, shown to be a STAT5 inhibitor, demonstrated a
concentration dependent reduction in STAT5 activity and in the number
of viable cells in PTCL lines.40
Further studies are underway to explore whether the reduction in
STAT5 phosphorylation is the result of DUSP4 induced expression by PDX.
In summary, our PDX resistant cell line models represent useful
paradigms (a) to elucidate the molecular mechanisms of action of
PDX, (b) to clarify the mechanisms underlying clinical resistance to the
drug, and (c) to evaluate new therapeutic strategies aimed at over-
come drug resistance.
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